Insulet shares surge 6.65% premarket after Q3 results beat estimates, revenue jumps 29.9% and guidance raised.

Insulet surged 6.65% in premarket trading following the release of its Q3 2025 results, which exceeded revenue and earnings estimates and included raised full-year guidance. The company reported $706.3 million in revenue, a 29.9% year-over-year increase, with adjusted EPS of $1.24, surpassing analyst expectations. Strong demand for its Omnipod 5 insulin pump, integration with Dexcom’s G7 CGM in Europe, and reimbursement expansions in Norway were highlighted. Insulet also raised 2025 revenue guidance to 28-29% growth (from 24-27%) and projected 22.7% adjusted EBITDA margins. The stock’s rally aligns with the positive earnings surprise, operational momentum, and expanded margin outlook, reflecting investor confidence in the company’s market leadership and product innovation.